Blood disorders do not affect all adults in the same way, and neither does their treatment. The haematologist who sees a 30-year-old with acute leukaemia and the one who sees a 72-year-old with the same diagnosis are not simply treating the same disease in different bodies. They are making fundamentally different decisions about which treatment the patient can tolerate, which treatment offers the best balance of benefit against harm, and what the realistic goals of care are. Age is not a barrier to treatment for blood disorders the 2025 American Society of Haematology guidelines for AML in older adults are explicit that age alone should not determine treatment eligibility. But age is one of the most clinically significant variables in haematology, shaping nearly every decision from chemotherapy dosing through bone marrow transplant eligibility to the choice between curative intent and disease control.
This guide explains how age affects treatment decisions across the major adult blood disorders and what international patients need to know when seeking specialist haematological care in India.
Why Age Shapes Treatment for Blood Disorders in Adults
Age affects the treatment of blood disorders through four distinct mechanisms that a haematologist weighs simultaneously for every patient.
Organ Reserve and Treatment Tolerance
Chemotherapy agents that are standard in younger adults are dose-limited or contraindicated in older patients because of reduced organ reserve. The kidneys clear cytotoxic drugs at different rates across age groups. The heart tolerates anthracyclines less well in patients with age-related myocardial changes. The bone marrow of a 70-year-old recovers from intensive chemotherapy more slowly than that of a 30-year-old, extending the period of dangerous neutropenia. These are not absolute restrictions they are factors that modify dosing, timing, and agent selection.
Comorbidity Burden
Most adults over 65 presenting with a blood disorder carry one or more coexisting conditions hypertension, diabetes, chronic kidney disease, prior cardiac disease, or chronic lung disease that interact with the proposed treatment. A patient with an ejection fraction of 40 percent cannot safely receive full-dose doxorubicin. A patient with eGFR 35 cannot receive standard-dose methotrexate without dose adjustment. Comorbidity assessment is a required component of treatment planning in older adults with blood disorders, not an optional addition.
Disease Biology That Shifts With Age
Blood cancers diagnosed in older adults tend to carry worse molecular risk profiles than the same cancer in younger patients. AML is the most common acute leukaemia in adults, with a median age of 68 years at presentation, and the proportion of patients with adverse-risk cytogenetics increases with age. Older AML patients are more likely to have secondary AML arising from prior myelodysplastic syndrome or prior treatment, which carries worse outcomes than de novo AML. This age-associated biology is an independent driver of treatment decisions separate from the patient's physical fitness.
Geriatric Assessment for Older Adults
For patients over 65 with blood disorders, the 2025 ASH AML guidelines recommend that fitness eligibility for conventional therapy be assessed using a formal geriatric assessment covering functional status, nutritional status, cognition, psychological state, social support, and cumulative illness rating not age alone or a single performance status score. This multidimensional assessment is what the guideline term fitness-based treatment selection means in practice.
Treatment for Blood Disorders by Age Group and Condition
Clinical management of hematological conditions is strictly guided by a patient's biological age, overall fitness, and specific molecular risk profile. Leading hematology centres balance intensive, curative approaches like stem cell transplants with targeted oral therapies to maximize remission while minimizing organ toxicity across every stage of life.
Acute Leukaemias
Younger Adults (18 to 55)
Young adults with acute leukaemia can generally tolerate the most intensive treatment approaches, which are also the ones most likely to produce cure. For AML, intensive induction chemotherapy (typically cytarabine plus an anthracycline the 7+3 regimen) followed by consolidation with high-dose cytarabine at 3g/m² is the evidence-based standard. Young adults with high-risk cytogenetics or MRD positivity after induction are candidates for allogeneic bone marrow transplant in first remission.
Young adults with ALL benefit particularly from paediatric-inspired protocols. In view of the superior outcomes of young adults treated with paediatric protocols compared to patients treated with adult protocols, it is strongly recommended that young adults up to their 30th birthday be treated on paediatric protocols where possible. This recommendation reflects decades of evidence showing that paediatric-intensity ALL regimens produce significantly better outcomes in young adults than the less intensive adult regimens historically applied to this age group.
Blinatumomab (a bispecific T-cell engager against CD19 and CD3) and inotuzumab ozogamicin (an anti-CD22 antibody-drug conjugate) are now integrated into frontline ALL treatment at many centres and are available at India's leading haematology centres.
Middle-Aged Adults (55 to 70)
Patients in this range require individualised assessment. Many are fit enough for intensive chemotherapy and transplant, but the probability of achieving long-term cure with intensive therapy begins to decline with age-associated disease biology. Cytarabine dosing is often modified in patients above 60: high-dose cytarabine consolidation uses 1.5g/m² rather than 3g/m² for patients over 60, based on the evidence that higher doses do not improve outcomes and significantly increase toxicity in this age group.
Reduced-intensity conditioning (RIC) regimens for allogeneic transplant allow patients up to 70 and sometimes older to proceed to transplant who would not tolerate a standard myeloablative conditioning regimen. RIC transplant achieves lower transplant-related mortality than myeloablative conditioning at the cost of slightly higher relapse rates a trade-off that may be appropriate in the 55 to 70 age group.
Older Adults (70 and above)
The 2025 ASH guidelines for AML in older adults represent the most current clinical framework for this age group. The panel agreed on nine critical clinical recommendations, including the decision to pursue antileukemic treatment versus best supportive management based on multidimensional geriatric assessment. Older adults with AML representing a cancer population in which disease-based risk factors, comorbidities, patient goals, and treatment risks and benefits all influence the recommendation.
For fit older adults with AML, the venetoclax plus azacitidine combination has transformed the treatment landscape, producing complete remission rates of 66 percent versus 28 percent for azacitidine alone in the VIALE-A trial. Venetoclax combined with hypomethylating agents produces meaningful disease control without the toxicity of intensive 7+3 induction, making it the preferred treatment for most older adults with newly diagnosed AML. Targeted agents including ivosidenib for IDH1-mutated AML and enasidenib for IDH2-mutated disease are NICE-approved and available at India's leading haematology centres.
Lymphomas
Hodgkin Lymphoma
Hodgkin lymphoma has a bimodal age distribution, peaking in young adults aged 20 to 34 and again in adults over 55. Treatment decisions differ significantly between the two groups.
Young adults with Hodgkin lymphoma are treated with ABVD or escalated BEACOPP chemotherapy with excellent cure rates. PET-adapted de-escalation reduces long-term treatment toxicity without compromising cure allowing PET-negative mid-treatment patients to switch from more intensive to less intensive regimens based on early response.
Older adults with Hodgkin lymphoma have worse outcomes than younger patients from the same disease, in part because of the higher proportion of adverse prognostic factors and in part because of reduced tolerance for the anthracycline and bleomycin components of standard regimens. NABVD (replacing dacarbazine) and brentuximab vedotin-containing regimens are increasingly used in older patients where the standard ABVD toxicity profile is prohibitive.
Non-Hodgkin Lymphoma (NHL)
Diffuse large B-cell lymphoma (DLBCL), the most common aggressive NHL, is treated with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone) in most patients regardless of age, but dosing modifications and prophylactic growth factor support (G-CSF) are standard in patients over 70. For very elderly patients with significant cardiac disease where full-dose doxorubicin is contraindicated, R-mini-CHOP or etoposide-substituted regimens preserve rituximab plus alkylating agent benefit with reduced cardiotoxicity.
Autologous stem cell transplant for relapsed DLBCL is offered to fit patients up to approximately 70 years, with careful performance status and organ function assessment guiding eligibility. CAR-T cell therapy (axicabtagene ciloleucel, tisagenlecleucel, lisocabtagene maraleucel) for relapsed or refractory DLBCL has dramatically changed outcomes for patients who fail second-line therapy and is now available at select advanced haematology centres in India. The 2025 EBMT recommendations confirm CAR-T for adult ALL and aggressive B-cell lymphoma as established indications at approved centres.
Chronic Leukaemias
Chronic Lymphocytic Leukaemia (CLL)
CLL is the most common adult leukaemia, predominantly affecting patients over 60. Treatment decisions are driven by biological markers del 17p and TP53 mutation status most importantly rather than age alone.
Ibrutinib, acalabrutinib, and zanubrutinib (BTK inhibitors) and venetoclax-based combinations have replaced chemotherapy as the standard of care for most CLL patients regardless of age. A real-world 2025 Italian multicentre study of 155 adults with CLL treated with acalabrutinib monotherapy found a median age of 74 years, with 44.5 percent of patients aged 75 or above confirming the applicability of modern targeted therapy in elderly CLL patients with significant comorbidities.
BTK inhibitors in particular are highly appropriate for older CLL patients because they are oral, well-tolerated, and do not require intensive inpatient chemotherapy admission. The main age-related consideration is cardiovascular atrial fibrillation occurs in approximately five to eight percent of patients on ibrutinib, and hypertension and bleeding events require monitoring in older patients on any BTK inhibitor.
Chronic Myeloid Leukaemia (CML)
CML is treated with tyrosine kinase inhibitors (TKIs) imatinib, dasatinib, nilotinib, bosutinib, or ponatinib as oral daily medications. Age affects TKI choice through cardiovascular and pulmonary risk considerations: dasatinib carries a risk of pleural effusion higher in older patients; nilotinib carries cardiovascular risk in patients with prior arterial disease; ponatinib carries thrombotic risk requiring careful patient selection in older adults.
For CML in chronic phase with appropriate TKI response, allogeneic transplant is no longer recommended as a first-line treatment in children and adolescents or in adults TKI therapy has made transplant unnecessary except for blast phase CML or TKI failure.
Anaemias and Bone Marrow Failure
Iron Deficiency Anaemia
The most common blood disorder in adults globally. Iron replacement (oral ferrous sulfate or parenteral iron infusion for patients with poor GI absorption or intolerance) is highly effective regardless of age. The key age consideration is investigation of cause: occult gastrointestinal bleeding is the most important underlying cause in adults over 50, requiring upper and lower GI endoscopy before iron replacement alone is considered sufficient management.
Aplastic Anaemia
For severe aplastic anaemia in younger adults (under 50) with a matched sibling donor, allogeneic bone marrow transplant is first-line treatment. For older adults without a sibling donor or who are not fit for transplant, immunosuppressive therapy with horse anti-thymocyte globulin (hATG) plus cyclosporine plus eltrombopag is the evidence-based alternative, producing complete response in 30 to 40 percent of patients.
Myelodysplastic Syndrome (MDS)
MDS has a median age at diagnosis of approximately 70 years. Low-risk MDS is managed with supportive care, erythropoiesis-stimulating agents, and transfusion support. Higher-risk MDS (IPSS-R intermediate-2 and high risk) requires disease-modifying treatment with hypomethylating agents (azacitidine, decitabine) or allogeneic transplant in fit patients. In older adults with higher-risk MDS, the venetoclax plus azacitidine combination approved for AML is being evaluated for MDS in ongoing trials and is being applied off-protocol at leading centres.
How India's Haematology Centres Incorporate Age Into Treatment Decisions
India's leading NABH-accredited haematology centres follow the international guidelines ASH, EBMT, ELN that incorporate age-based fitness assessment into every treatment decision. For international patients from Oman, Nigeria, Bangladesh, Kenya, and the UAE who arrive at Indian centres without having had a formal geriatric fitness assessment or molecular profiling, the first step is completing this evaluation before any treatment recommendation is finalised.
Molecular Profiling at Indian Haematology Centres
India's leading haematology centres perform comprehensive molecular profiling cytogenetics, next-generation sequencing panels for AML (FLT3, NPM1, CEBPA, IDH1/2, TP53, RUNX1, ASXL1), Philadelphia chromosome and BCR-ABL quantification for ALL and CML, and TP53 and del 17p testing for CLL before any treatment is designed. This molecular foundation is what allows targeted agents to be selected appropriately: venetoclax plus azacitidine for older AML patients, ivosidenib for IDH1-mutated AML, acalabrutinib or zanubrutinib for del17p CLL regardless of age.
CAR-T and Advanced Therapies
CAR-T cell therapy for relapsed or refractory B-cell lymphoma and ALL is available at select advanced oncology centres in India, including Apollo Proton Cancer Centre Chennai, AIIMS Delhi, and Tata Medical Centre Kolkata. These therapies are increasingly accessible to international patients at costs substantially below Western markets.
Cost of Blood Disorder Treatment in India for International Patients
| Treatment | India cost | USA equivalent |
|---|---|---|
| Haematology consultation and molecular profiling | Rs. 5,000 to Rs. 25,000 (USD 60 to USD 300) | USD 1,000 to USD 5,000 |
| Chemotherapy per cycle (induction AML) | Rs. 30,000 to Rs. 80,000 (USD 360 to USD 960) | USD 5,000 to USD 20,000 |
| Venetoclax plus azacitidine per cycle | Rs. 40,000 to Rs. 80,000 (USD 480 to USD 960) | USD 8,000 to USD 25,000 |
| BTK inhibitor (acalabrutinib/ibrutinib per month) | Rs. 15,000 to Rs. 40,000 (USD 180 to USD 480) | USD 8,000 to USD 15,000 |
| Autologous BMT | Rs. 8,00,000 to Rs. 15,00,000 (USD 9,600 to USD 18,000) | USD 80,000 to USD 150,000 |
| Allogeneic BMT (related donor) | Rs. 18,00,000 to Rs. 30,00,000 (USD 21,600 to USD 36,000) | USD 150,000 to USD 300,000 |
| CAR-T cell therapy | Rs. 30,00,000 to Rs. 50,00,000 (USD 36,000 to USD 60,000) | USD 400,000 to USD 600,000 |
How Karetrip Connects International Adults With Blood Disorders to the Right Specialist in India
Blood disorder treatment in adults requires a haematologist who understands the age-specific treatment framework for the specific diagnosis not a generalist who applies the same protocol regardless of patient age and fitness. Karetrip reviews each patient's haematology reports, molecular profiling results, and prior treatment history before recommending an Indian haematology centre, confirming the proposed team has the age-appropriate treatment capability and molecular profiling infrastructure the case requires.
Chat with our Medical care assistant, RUA, for quick guidance and support and take the first step toward specialist blood disorder treatment at India's leading haematology centres.
Medical Disclaimer
This article is for informational purposes only and does not constitute medical advice. Blood disorders require evaluation by a qualified haematologist. All treatment decisions must be made by your treating specialist team based on your individual clinical situation and age-related fitness assessment.